Mesoblast Net Receivables vs Total Revenue Analysis

MESO Stock

USD 18.69 0.13 0.69%

Mesoblast financial indicator trend analysis is infinitely more than just investigating Mesoblast recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mesoblast is a good investment. Please check the relationship between Mesoblast Net Receivables and its Total Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Net Receivables vs Total Revenue

Net Receivables vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mesoblast Net Receivables account and Total Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Mesoblast's Net Receivables and Total Revenue is -0.12. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Mesoblast, assuming nothing else is changed. The correlation between historical values of Mesoblast's Net Receivables and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Mesoblast are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Net Receivables i.e., Mesoblast's Net Receivables and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.12

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Total Revenue

Total revenue comprises all receipts Mesoblast generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Mesoblast's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mesoblast current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.As of the 7th of February 2025, Enterprise Value is likely to grow to about 1.2 B, while Selling General Administrative is likely to drop about 20.5 M.

	2022	2023	2024	2025 (projected)
Interest Income	831K	1.8M	2.1M	2.2M
Reconciled Depreciation	4.1M	4.7M	5.4M	4.0M

Interest Income Reconciled Depreciation

Mesoblast fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Current Deferred Revenue	Good Will	Non Current Liabilities Total	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Inventory
Total Assets		0.04	0.45	0.95	0.34	-0.07	-0.11	0.68	0.06	0.94	0.06	0.1	-0.02	0.3	0.08	0.88	0.04	0.63	0.94	-0.15	0.64	0.24	0.26	0.0	0.06	-0.15
Other Current Liab	0.04		0.72	0.07	0.07	0.46	-0.64	-0.35	0.15	0.08	0.15	0.37	0.73	-0.09	-0.09	-0.01	0.59	-0.07	0.07	-0.25	0.34	-0.38	-0.06	-0.1	0.54	-0.42
Total Current Liabilities	0.45	0.72		0.48	0.65	0.2	-0.64	0.15	0.45	0.45	0.45	0.07	0.58	0.14	0.4	0.33	0.56	0.23	0.43	-0.57	0.49	-0.3	0.12	-0.23	0.6	-0.46
Total Stockholder Equity	0.95	0.07	0.48		0.39	-0.01	-0.22	0.67	0.11	0.92	0.11	0.16	0.03	0.35	0.16	0.7	0.08	0.55	0.91	-0.24	0.54	-0.04	0.35	-0.05	0.2	-0.32
Property Plant And Equipment Net	0.34	0.07	0.65	0.39		0.1	-0.49	0.43	0.37	0.37	0.37	-0.31	0.3	0.16	0.68	0.19	0.47	0.09	0.35	-0.62	0.26	-0.26	0.15	-0.16	0.57	-0.4
Net Debt	-0.07	0.46	0.2	-0.01	0.1		-0.67	-0.1	-0.56	0.08	-0.56	0.28	0.6	0.25	-0.11	-0.16	0.6	-0.39	0.07	-0.15	0.37	-0.27	-0.06	0.0	0.56	-0.59
Retained Earnings	-0.11	-0.64	-0.64	-0.22	-0.49	-0.67		0.06	-0.17	-0.3	-0.17	-0.21	-0.86	-0.18	-0.23	0.09	-0.88	0.38	-0.27	0.44	-0.37	0.6	-0.03	0.07	-0.93	0.84
Accounts Payable	0.68	-0.35	0.15	0.67	0.43	-0.1	0.06		-0.14	0.7	-0.14	-0.2	-0.3	0.39	0.16	0.58	-0.12	0.29	0.71	0.0	0.56	0.25	0.57	-0.06	-0.13	-0.2
Cash	0.06	0.15	0.45	0.11	0.37	-0.56	-0.17	-0.14		0.02	1.0	-0.05	0.15	-0.06	0.52	-0.02	0.15	0.12	-0.01	-0.29	-0.22	-0.36	-0.05	-0.23	0.28	-0.06
Non Current Assets Total	0.94	0.08	0.45	0.92	0.37	0.08	-0.3	0.7	0.02		0.02	0.1	0.08	0.4	0.12	0.79	0.15	0.32	1.0	-0.15	0.75	0.11	0.39	-0.05	0.25	-0.42
Cash And Short Term Investments	0.06	0.15	0.45	0.11	0.37	-0.56	-0.17	-0.14	1.0	0.02		-0.05	0.15	-0.06	0.52	-0.02	0.15	0.12	-0.01	-0.29	-0.22	-0.36	-0.05	-0.23	0.28	-0.06
Net Receivables	0.1	0.37	0.07	0.16	-0.31	0.28	-0.21	-0.2	-0.05	0.1	-0.05		0.29	0.33	-0.35	-0.02	0.14	0.04	0.1	0.03	0.15	-0.18	0.18	0.27	0.16	-0.22
Common Stock Shares Outstanding	-0.02	0.73	0.58	0.03	0.3	0.6	-0.86	-0.3	0.15	0.08	0.15	0.29		-0.15	-0.03	-0.1	0.94	-0.23	0.05	-0.45	0.29	-0.44	-0.18	0.28	0.77	-0.52
Other Current Assets	0.3	-0.09	0.14	0.35	0.16	0.25	-0.18	0.39	-0.06	0.4	-0.06	0.33	-0.15		0.38	0.17	-0.13	-0.08	0.4	-0.09	0.39	-0.07	0.44	-0.42	0.17	-0.45
Other Stockholder Equity	0.08	-0.09	0.4	0.16	0.68	-0.11	-0.23	0.16	0.52	0.12	0.52	-0.35	-0.03	0.38		-0.06	0.09	-0.04	0.09	-0.36	-0.1	-0.37	-0.01	-0.55	0.36	-0.29
Total Liab	0.88	-0.01	0.33	0.7	0.19	-0.16	0.09	0.58	-0.02	0.79	-0.02	-0.02	-0.1	0.17	-0.06		-0.03	0.64	0.81	0.01	0.67	0.62	0.06	0.08	-0.17	0.14
Property Plant And Equipment Gross	0.04	0.59	0.56	0.08	0.47	0.6	-0.88	-0.12	0.15	0.15	0.15	0.14	0.94	-0.13	0.09	-0.03		-0.23	0.12	-0.33	0.31	-0.38	-0.25	0.17	0.79	-0.54
Total Current Assets	0.63	-0.07	0.23	0.55	0.09	-0.39	0.38	0.29	0.12	0.32	0.12	0.04	-0.23	-0.08	-0.04	0.64	-0.23		0.33	-0.08	0.05	0.4	-0.17	0.11	-0.39	0.53
Intangible Assets	0.94	0.07	0.43	0.91	0.35	0.07	-0.27	0.71	-0.01	1.0	-0.01	0.1	0.05	0.4	0.09	0.81	0.12	0.33		-0.13	0.76	0.15	0.39	-0.03	0.21	-0.39
Current Deferred Revenue	-0.15	-0.25	-0.57	-0.24	-0.62	-0.15	0.44	0.0	-0.29	-0.15	-0.29	0.03	-0.45	-0.09	-0.36	0.01	-0.33	-0.08	-0.13		-0.13	0.35	-0.21	-0.19	-0.5	0.31
Good Will	0.64	0.34	0.49	0.54	0.26	0.37	-0.37	0.56	-0.22	0.75	-0.22	0.15	0.29	0.39	-0.1	0.67	0.31	0.05	0.76	-0.13		0.28	0.42	0.07	0.26	-0.43
Non Current Liabilities Total	0.24	-0.38	-0.3	-0.04	-0.26	-0.27	0.6	0.25	-0.36	0.11	-0.36	-0.18	-0.44	-0.07	-0.37	0.62	-0.38	0.4	0.15	0.35	0.28		-0.16	0.25	-0.68	0.65
Short Term Debt	0.26	-0.06	0.12	0.35	0.15	-0.06	-0.03	0.57	-0.05	0.39	-0.05	0.18	-0.18	0.44	-0.01	0.06	-0.25	-0.17	0.39	-0.21	0.42	-0.16		0.04	0.03	-0.45
Non Currrent Assets Other	0.0	-0.1	-0.23	-0.05	-0.16	0.0	0.07	-0.06	-0.23	-0.05	-0.23	0.27	0.28	-0.42	-0.55	0.08	0.17	0.11	-0.03	-0.19	0.07	0.25	0.04		-0.12	0.25
Common Stock Total Equity	0.06	0.54	0.6	0.2	0.57	0.56	-0.93	-0.13	0.28	0.25	0.28	0.16	0.77	0.17	0.36	-0.17	0.79	-0.39	0.21	-0.5	0.26	-0.68	0.03	-0.12		-0.78
Inventory	-0.15	-0.42	-0.46	-0.32	-0.4	-0.59	0.84	-0.2	-0.06	-0.42	-0.06	-0.22	-0.52	-0.45	-0.29	0.14	-0.54	0.53	-0.39	0.31	-0.43	0.65	-0.45	0.25	-0.78

Click cells to compare fundamentals

Mesoblast Account Relationship Matchups

Mesoblast fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	744.7M	662.1M	669.4M	669.2M	769.5M	583.1M
Other Current Liab	18.7M	2.2M	5.4M	49.7M	57.1M	60.0M
Total Current Liabilities	94.3M	51.4M	42.0M	73.2M	84.2M	88.4M
Total Stockholder Equity	581.4M	497.0M	501.8M	480.4M	552.4M	419.6M
Property Plant And Equipment Net	12.1M	10.0M	6.5M	3.8M	4.4M	3.6M
Net Debt	(31.4M)	46.9M	45.6M	56.4M	64.8M	68.1M
Retained Earnings	(647.6M)	(738.9M)	(820.8M)	(908.8M)	(817.9M)	(777.0M)
Accounts Payable	19.6M	23.1M	20.1M	7.1M	8.1M	15.1M
Cash	136.9M	60.0M	70.9M	62.6M	71.9M	67.2M
Non Current Assets Total	596.5M	592.3M	587.8M	582.7M	670.1M	466.6M
Cash And Short Term Investments	136.9M	60.0M	70.9M	62.6M	71.9M	67.2M
Net Receivables	4.6M	4.4M	2.3M	21.0M	24.1M	25.3M
Common Stock Shares Outstanding	605.1M	682.9M	839.3M	986.7M	1.1B	1.2B
Liabilities And Stockholders Equity	744.7M	662.1M	669.4M	669.2M	769.5M	583.1M
Other Current Assets	7.2M	5.4M	3.7M	2.6M	2.9M	3.9M
Other Stockholder Equity	1.1B	1.2B	1.2B	73.5M	84.5M	80.3M
Total Liab	163.3M	165.1M	167.6M	188.8M	217.1M	163.4M
Property Plant And Equipment Gross	12.1M	28.3M	28.5M	24.1M	27.7M	29.1M
Total Current Assets	148.2M	69.8M	81.7M	86.5M	99.4M	116.5M
Accumulated Other Comprehensive Income	65.8M	70.7M	73.5M	78.3M	90.0M	46.0M
Intangible Assets	446.1M	444.2M	442.7M	441.3M	507.5M	352.8M
Non Current Liabilities Total	69.0M	113.7M	125.6M	115.6M	104.0M	128.2M
Short Term Debt	56.0M	8.2M	10.0M	16.5M	19.0M	25.5M
Non Currrent Assets Other	1.7M	1.7M	481K	2.1M	1.9M	2.0M
Inventory	(4.1M)	(1.6M)	(252K)	(4.3M)	(3.9M)	(3.7M)
Common Stock	1.2B	1.2B	1.2B	1.3B	1.5B	1.0B
Other Liab	30.8M	19.5M	15.0M	19.1M	17.2M	16.3M
Net Tangible Assets	(32.3M)	851K	(81.6M)	(75.3M)	(86.6M)	(91.0M)
Other Assets	3.3M	1.7M	1.9M	2.3M	2.1M	2.0M
Property Plant Equipment	10.3M	12.1M	10.0M	6.5M	7.5M	6.0M
Long Term Investments	2.1M	1.8M	1.8M	1.0M	912.6K	1.6M
Net Invested Capital	675.6M	593.7M	610.6M	594.7M	683.9M	659.7M
Net Working Capital	54.0M	18.5M	39.7M	13.2M	11.9M	11.3M
Short Long Term Debt Total	105.5M	106.9M	116.5M	118.9M	136.8M	108.1M
Long Term Debt	41.0M	91.6M	102.8M	100.5M	115.6M	81.7M
Short Long Term Debt	53.2M	5.0M	6.0M	13.9M	12.5M	21.0M

When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:

How To Invest In Mesoblast

Details

Is Mesoblast Stock a good investment?

Details

What is Mesoblast's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.05)

Revenue Per Share

0.06

Quarterly Revenue Growth

(0.41)

Return On Assets

(0.05)

Return On Equity

(0.18)

The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mesoblast Net Receivables vs Total Revenue Analysis

Net Receivables vs Total Revenue

Net Receivables vs Total Revenue Correlation Analysis

Correlation Coefficient

Net Receivables

Total Revenue

Mesoblast fundamental ratios Correlations

Mesoblast Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mesoblast fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Intangible Assets	+ 1.0	Non Current Assets Total
Total Stockholder Equity	+ 0.95	Total Assets
Non Current Assets Total	+ 0.94	Total Assets
Intangible Assets	+ 0.94	Total Assets
Property Plant And Equipment Gross	+ 0.94	Common Stock Shares Outstanding

Common Stock Total Equity	- 0.93	Retained Earnings
Property Plant And Equipment Gross	- 0.88	Retained Earnings
Common Stock Shares Outstanding	- 0.86	Retained Earnings
Inventory	- 0.78	Common Stock Total Equity
Common Stock Total Equity	- 0.68	Non Current Liabilities Total
Retained Earnings	- 0.67	Net Debt